Table 1.
Characteristics of single-arm studies evaluating Tocilizumab in COVID 19 patients.
| Author, month, year | Country | Type of study | Patients n (males) | Age in years (Mean ± SD or median with range) | Comorbidities | Severity | Treatment | Mortality in % |
|---|---|---|---|---|---|---|---|---|
| Alattar, April 2020 (21) | Qatar | Retrospective | 25 (23) | 58 (50–63) | Diabetes- 48% CKD 16% Cardiac 12% |
Critical 100% | TCZ±H, L/R, R* | 12% |
| Alberici, April 2020 (22) | Italy | Retrospective | 20 (16) | 59 (51–64) | Renal transplant patients | Severe 13% Critical -none |
TCZ +/- H | 25% |
| Uysal June 2020 (23) | Turkey | Retrospective | 12 (6) | 65 ± 11.3 | Diabetes 58% Hypertension 58% |
Severe 83% Critical 17% |
TCZ+H, O | 0% |
| Hassoun July 2020 (24) | USA | Retrospective | 9 (6) | 60 (37–88) | Diabetes 11% Hypertension 44% Cardiac 11% Obesity 33% |
Severe 55% Critical 44% |
TCZ + corticosteroids | 22% |
| Luo, March 2020 (16) | China | Retrospective | 15 (12) | 73 (62–80) | Diabetes 26% Hypertension 60% |
Severe 40% Critical 46.7% |
TCZ+methyl prednisolone | 20% |
| Marfella, May 2020 (25) | Italy | Retrospective | 78 (55) | 65.7 ± 13.4 | Hyperglycemia (39.7%) | NA | TCZ | NA |
| Morena, May 2020 (26) | Italy | Prospective | 51 (40) | 60 (50–70) | Cardiovascular diseases 49% Hypertension 29.4% Diabetes 11.9% |
Severe 88% Critical – 11.7% |
TCZ ±H, L/R, R | 27% |
| Sciascia, May, 2020 (27) | Italy | Prospective | 63 (56) | 62.6 ± 12.5 | NA | Severe 100% | TCZ | 11% |
| Toniati, July 2020 (28) | Italy | Prospective | 100 (88) | 62 (57–71) | Diabetes 17% Hypertension 46% CKD 11% COPD 9% |
Severe 57% Critical 43% |
TCZ | 20% |
| Xu, April 2020 (29) | China | Retrospective | 21 (18) | 56.8 ± 16.5 (25–88) | Hypertension 43% Diabetes 23.8% Cardiac 9.5% COPD 4.8% |
Severe 81% Critical 19% |
TCZ | 0% |
TCZ, Tocilizumab; H, Hydroxychloroquine; L/R, Lopinavir/Ritonavir; R*, Ribavirin; R, Remdesivir; O, Oseltamivir; SD, Standard Deviation; CKD, Chronic Kidney Disease; NA, Not applicable; COPD, Chronic Obstructive Pulmonary Disease.